Enveric Biosciences, Inc. (ENVB) stock
Close on Nov 11, 2026Market cap $6.67MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $6.67M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.83
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$8.73M
- EPS, diluted
- -$18.77
- Book value per share
- $2.03
- Diluted shares
- 4M
Trading
- Next earnings
- Nov 13, 2026 (estimated, during market hours)
- Previous close
- $1.51
- Open
- $1.38
- Day's range
- $1.38 – $1.58
- Volume
- 10,665
- Average volume (20 days)
- 31,792
- Beta (5 years)
- 1.16
- 52-week range
- $1.17 – $13.25
- RSI (14 days)
- 53.9
- Volatility (1 year)
- 160.8%
- Relative volume
- 0.12×
- WACC
- 10.7%
Market cap history
Month-end market cap since 2015, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | ENVB | S&P 500 | Difference | ENVB per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +2.8% | -2.4% | +5.2 pts | ||
| 3 months | -3.9% | -1.2% | −2.7 pts | ||
| Year to date | -59.0% | +12.3% | −71.2 pts | ||
| 1 year | -74.9% | +12.4% | −87.4 pts | ||
| 3 years | -100.0% | +78.8% | −178.8 pts | -93.0% | +21.4% |
| 5 years | -100.0% | +75.2% | −175.2 pts | -91.0% | +11.9% |
| 10 years | -100.0% | +311.1% | −411.1 pts | -83.3% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Enveric Biosciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- News
- News
- News
About Enveric Biosciences
Pharmaceutical Preparations
Enveric Biosciences is a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics to treat psychiatric and neurological disorders. Utilizing its drug discovery platform and proprietary Psybrary compound library, the company creates novel molecules designed to promote neuroplasticity without causing hallucinogenic effects. Its lead drug program is the EVM301 Series featuring drug candidate EB-003, a novel derivative of N,N-Dimethyltryptamine intended to engage serotonin receptors for neuropsychiatric conditions, alongside the EVM401 pipeline series. Its intended customers and partners include patients with limited therapeutic options, as well as pharmaceutical and biotechnology companies for potential development partnerships and licensing arrangements.
Company profile, executives and historyEnveric Biosciences stock: common questions
What is Enveric Biosciences's stock price?
ENVB closed at $1.49 on Nov 11, 2026, down 1.32% on the day. Over the past 52 weeks it traded between $1.17 and $13.25.
What is Enveric Biosciences's market cap?
Enveric Biosciences was worth $6.67M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is ENVB's P/E ratio?
Enveric Biosciences lost money over the twelve months to Jun 30, 2026 (diluted EPS -$18.77), so it has no meaningful P/E ratio.
Does Enveric Biosciences pay a dividend?
No. Enveric Biosciences has not paid a cash dividend over the last twelve months.
When does Enveric Biosciences report earnings next?
Enveric Biosciences is expected to report Q3 FY2026 results on Nov 13, 2026, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has ENVB stock performed over the past year?
Including dividends, ENVB returned -74.9% over the past year, against +12.4% for the S&P 500.
How many ENVB shares are sold short?
0M shares were sold short at the latest FINRA report, 0.74% of the float, or 1.0 days of average trading volume.
Who are Enveric Biosciences's competitors?
Companies most similar to Enveric Biosciences by business, industry and size include PBM, PTIX, RAPP, NERV, CMPS.
See a number that looks wrong?